Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Status: Not yet enrolling

Conditions: Nasopharyngeal Carcinoma (NPC)

Treatments: Other: No Intervention

Study type: Observational

Funder types: Other

Identifiers

NCT07198802

WuhanUH 1149-01

Details and patient eligibility

About

To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2~3 key cell subsets or node molecules were screened to predict the curative effect. Spatial metabolome and organoids were used to elucidate the mechanism of key factors leading to immunotherapy tolerance in NPC and identify new targets for intervention.

Enrollment: 600 estimated patients

Sex: All

Ages: 15 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria Before the trial, the participants must meet all of the following requirements to be eligible for inclusion.

1. Clearly diagnosed with nasopharyngeal carcinoma by pathology;
2. Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital;
3. Patients diagnosed in our hospital from January 2025 to December 2028;
4. Have relatively complete clinical data;
5. Age between 15 and 75 years old;

Exclusion Criteria Before the trial, the participants who meet any of the following requirements cannot be included.

1. The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.;
2. The participants failed to obtain pathological and imaging data for various reasons;
3. Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.

Trial design

600 participants in 1 patient group

Study Groups

Treatment:

Other: No Intervention